COMBINATION THERAPY FOR INHIBITION OF PLATELET AGGREGATION
    3.
    发明申请
    COMBINATION THERAPY FOR INHIBITION OF PLATELET AGGREGATION 审中-公开
    组合治疗抑制血小板聚集

    公开(公告)号:US20100041587A1

    公开(公告)日:2010-02-18

    申请号:US12540062

    申请日:2009-08-12

    IPC分类号: A61K38/16 A61K31/727

    摘要: The invention features methods for preventing platelet activation and aggregation and for treating individuals suffering from conditions or undergoing procedures that may result in unwanted platelet aggregation. The methods are based on the intravenous, subcutaneous, or transdermal administration of a platelet activation or aggregation inhibitor, e.g., xemilofiban, followed by oral administration of the same or a different platelet activation or aggregation inhibitor. The treatment may commence prior to a medical or surgical procedure or after the outbreak of an adverse medical condition, either of which results in the activation of platelets that may lead to thrombus formation, and may continue thereafter.

    摘要翻译: 本发明的特征在于防止血小板活化和聚集以及治疗患有可能导致不想要的血小板聚集的病症或经历程序的个体的方法。 该方法基于静脉内,皮下或透皮给药血小板活化或聚集抑制剂,例如替莫非溴,然后口服施用相同或不同的血小板活化或聚集抑制剂。 治疗可以在医疗或手术过程之前或在不良医学状况爆发之后开始,其中任何一种导致血小板的激活,其可能导致血栓形成,并且可以继续。